A gut bacteria metabolite called imidazole propionate may directly accelerate the brain changes linked to Alzheimer’s disease, a study suggests. Researchers found that higher blood levels of the molecule correlate with worse cognitive decline in people and actively drive neurodegeneration in mice, with the work published in Nature Communications.
The human digestive tract hosts trillions of bacteria that aid digestion. As they break down food, these microbes release chemical byproducts into the bloodstream, which travel to organs including the brain and can influence their function.
Imidazole propionate is produced when gut bacteria break down histidine, an amino acid found in many everyday foods. Previous research has tied elevated levels of this metabolite to metabolic conditions such as type 2 diabetes and heart disease, and given that metabolic problems often accompany dementia, scientists hypothesised the chemical might also affect brain health.
Led by Vaibhav Vemuganti and Jea Woo Kang from the University of Wisconsin–Madison, the study also involved senior authors Barbara B. Bendlin and Federico E. Rey. Their aim was to test whether imidazole propionate can influence the biological pathways involved in cognitive ageing and Alzheimer’s disease.
In the first phase, the team analysed blood samples from nearly 1,200 older adults, most without diagnosed cognitive impairment. They measured the concentration of imidazole propionate and compared it with performance on standard memory and problem‑solving tests, adjusting for age, sex, body mass index and the APOE gene, a known genetic risk factor for Alzheimer’s.
Participants with the highest metabolite levels performed worse on cognitive tests at baseline. Over several years of follow‑up, these individuals showed an earlier and more rapid decline in memory and executive function than those with lower levels. Modelling suggested the high‑metabolite group would fall below the performance of the low‑metabolite group roughly 15 to 18 years before the average participant reached their age at the start of the study.
To probe physical brain changes, the researchers measured molecular markers of Alzheimer’s disease in participants’ blood and cerebrospinal fluid. They found that high blood levels of imidazole propionate correlated with elevated tau tangles and higher levels of neurofilament light chain, a marker of neuronal damage that leaks from impaired brain cells.
In a separate analysis of gut bacteria, faecal samples from 294 participants were examined for the urdA gene, which encodes the enzyme that produces imidazole propionate. This gene appeared in several bacterial families, including certain Streptococcus strains, and a higher abundance of bacteria carrying urdA was linked to poorer cognitive scores and higher Alzheimer’s biomarkers.
The team then looked at large genetic databases to test whether naturally occurring genetic variation associated with higher metabolite levels also influenced Alzheimer’s risk. Using a Mendelian‑randomisation–style approach, they identified a genetic variant on chromosome 12 that leads some people to accumulate higher levels of imidazole propionate. Carrying this variant associated with an increased risk of developing Alzheimer’s disease, suggesting the metabolite may actively promote the condition rather than merely accompany it.
Two mouse models engineered to develop Alzheimer’s‑like brain changes were then used to test causality. In the first model that mimics amyloid plaque formation, mice given imidazole propionate in their drinking water developed more plaques than controls. In the second model, designed to model tau tangles, the metabolite triggered severe brain inflammation and activated astrocytes, a type of support cell, with proteomic analysis indicating broad structural disruption of nerve fibres.
Because the metabolite originates in the gut, researchers traced its route to the brain by assessing its effect on the blood–brain barrier. In human brain microvascular endothelial cells exposed to the chemical, the barrier’s electrical resistance fell, indicating compromised integrity. In a separate in vivo test, a blue dye injected into the bloodstream of treated mice leaked extensively into brain tissue, demonstrating barrier breakdown.
In cultured mouse neurons, exposure to imidazole propionate caused rapid accumulation of damaged tau proteins. When the researchers added a chemical inhibitor of the enzyme GSK3‑beta, which is known to aberrantly attach phosphate groups to tau, the effect was completely reversed, pointing to a specific molecular pathway through which the gut metabolite damages brain cells.
While the human data show a strong association, the researchers emphasise that they cannot prove causation from observation alone. They acknowledge that the animal studies used male mice and that the model may not fully replicate how the metabolite is produced and absorbed in humans.
Future work will need to test female animals to determine whether effects differ by sex and explore whether dietary modifications or targeted drugs could safely reduce the production of imidazole propionate in the gut.
The study, “Gut bacterial metabolite imidazole propionate potentiates Alzheimer’s disease pathology,” was led by Vaibhav Vemuganti and Jea Woo Kang, with senior authors Barbara B. Bendlin and Federico E. Rey, among others, and published in Nature Communications.
